Prestige Consumer Healthcare Stock (NYSE:PBH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$82.46

52W Range

$56.61 - $83.83

50D Avg

$73.68

200D Avg

$70.44

Market Cap

$4.08B

Avg Vol (3M)

$251.22K

Beta

0.47

Div Yield

-

PBH Company Profile


Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Show More

Industry

Medical - Distribution

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

570

IPO Date

Feb 10, 2005

Website

PBH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 24Mar 23Mar 22
Analgesics$117.45M--
Cough and Cold$119.02M--
Dermatologicals$129.10M--
Eye and Ear Care$179.42M--
Gastrointestinal$231.61M--
Oral Care$96.31M--
Other OTC$12.03M--
Women's Health$240.42M--
Product and Service, Other-$107.00K$42.00K
Product-$1.13B$1.09B

Fiscal year ends in Mar 24 | Currency in USD

PBH Financial Summary


Mar 24Mar 23Mar 22
Revenue$1.13B$1.13B$1.09B
Operating Income$342.43M$345.47M$329.92M
Net Income$209.34M$-82.31M$205.38M
EBITDA$373.10M$378.09M$360.96M
Basic EPS$4.21$-1.65$4.09
Diluted EPS$4.17$-1.65$4.04

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts


Q2 25Nov 09, 24 | 11:50 AM
Q2 24Aug 08, 24 | 11:20 AM
Q4 24May 15, 24 | 1:15 PM

Peer Comparison


TickerCompany
SUPNSupernus Pharmaceuticals, Inc.
ANIPANI Pharmaceuticals, Inc.
PAHCPhibro Animal Health Corporation
RGCRegencell Bioscience Holdings Limited
SSICSilver Spike Investment Corp.
DCPHDeciphera Pharmaceuticals, Inc.
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
EVOEvotec SE
EGRXEagle Pharmaceuticals, Inc.
AMPHAmphastar Pharmaceuticals, Inc.